Targeting prodromal Alzheimer's disease: too late for prevention?
作者信息
Yassine Hussein N
机构信息
Keck School of Medicine of USC, Los Angeles, CA 90033, USA.
出版信息
Lancet Neurol. 2017 Dec;16(12):946-947. doi: 10.1016/S1474-4422(17)30372-1. Epub 2017 Oct 30.
Abstract
摘要
相似文献
1
Targeting prodromal Alzheimer's disease: too late for prevention?针对前驱期阿尔茨海默病：预防是否为时已晚？
Lancet Neurol. 2017 Dec;16(12):946-947. doi: 10.1016/S1474-4422(17)30372-1. Epub 2017 Oct 30.
2
[Late life depression or prodromal Alzheimer's disease: Which tools for the differential diagnosis?].[老年期抑郁症还是阿尔茨海默病前驱期：哪些工具用于鉴别诊断？]
Encephale. 2018 Feb;44(1):52-58. doi: 10.1016/j.encep.2017.03.002. Epub 2017 Apr 20.
3
Exploring Alzheimer's disease subtypes at the prodromal stage.探索前驱期阿尔茨海默病的亚型。
Brain. 2018 Dec 1;141(12):3285-3287. doi: 10.1093/brain/awy282.
4
[Markers of prodromal Alzheimer's disease].[前驱期阿尔茨海默病的标志物]
Rev Neurol (Paris). 2012 Nov;168(11):815-24. doi: 10.1016/j.neurol.2012.07.005. Epub 2012 Sep 1.
5
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.脑脊液生物标志物（磷酸化tau181、总tau、Aβ42 和 Aβ40）在阿尔茨海默病和路易体痴呆前驱期的诊断价值。
J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.
6
The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.脑脊液生物标志物在阿尔茨海默病诊断标准演变中的作用：前驱期诊断的不足
J Alzheimers Dis. 2016 May 7;53(2):373-92. doi: 10.3233/JAD-160037.
7
Do preclinical Alzheimer's disease criteria work?临床前阿尔茨海默病标准有效吗？
Lancet Neurol. 2013 Oct;12(10):933-5. doi: 10.1016/S1474-4422(13)70217-5. Epub 2013 Sep 4.
8
Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant?癫痫前驱性阿尔茨海默病：13例新病例的回顾性研究——将阿尔茨海默病的范围扩展至癫痫变异型？
J Alzheimers Dis. 2016 Apr 18;52(3):1125-33. doi: 10.3233/JAD-150096.
9
Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project.前驱期阿尔茨海默病认知储备的代谢网络：欧洲阿尔茨海默病联合会项目。
J Nucl Med. 2013 Jun;54(6):894-902. doi: 10.2967/jnumed.112.113928. Epub 2013 Apr 16.
10
CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.CERAD 神经心理学复合评分能准确检测前驱期阿尔茨海默病：一项前瞻性 AddNeuroMed 研究。
J Alzheimers Dis. 2014;39(3):679-90. doi: 10.3233/JAD-122110.
引用本文的文献
1
Synthesis and Preclinical Evaluation of 22-[F]Fluorodocosahexaenoic Acid as a Positron Emission Tomography Probe for Monitoring Brain Docosahexaenoic Acid Uptake Kinetics.二十二碳六烯酸[F]标记物作为监测脑二十二碳六烯酸摄取动力学的正电子发射断层扫描探针的合成与临床前评价。
ACS Chem Neurosci. 2023 Dec 20;14(24):4409-4418. doi: 10.1021/acschemneuro.3c00681. Epub 2023 Dec 4.
2
Screening and predicting progression from high-risk mild cognitive impairment to Alzheimer's disease.筛查和预测高危轻度认知障碍向阿尔茨海默病的进展。
Sci Rep. 2021 Sep 2;11(1):17558. doi: 10.1038/s41598-021-96914-3.
3
ApoE and cerebral insulin: Trafficking, receptors, and resistance.载脂蛋白 E 和脑胰岛素：转运、受体和抵抗。
Neurobiol Dis. 2020 Apr;137:104755. doi: 10.1016/j.nbd.2020.104755. Epub 2020 Jan 21.
4
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.使用无监督学习的神经心理学测试表现的时间关联揭示了阿尔茨海默病状态的独特特征。
Alzheimers Dement (N Y). 2019 Dec 28;5:964-973. doi: 10.1016/j.trci.2019.11.006. eCollection 2019.
5
Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.J-ADNI 研究中 CSF Aβ 与纵向 SUVR 对 PiB 视觉解读的评估。
Ann Nucl Med. 2020 Feb;34(2):108-118. doi: 10.1007/s12149-019-01420-2. Epub 2019 Nov 20.
6
Souvenaid in the management of mild cognitive impairment: an expert consensus opinion.《关于轻度认知障碍管理的苏威艾得共识意见》。
Alzheimers Res Ther. 2019 Aug 17;11(1):73. doi: 10.1186/s13195-019-0528-6.
本文引用的文献
1
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.对前驱期阿尔茨海默病患者进行特定多种营养素的24个月干预（LipiDiDiet）：一项随机、双盲、对照试验。
Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0. Epub 2017 Oct 30.
2
Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review.二十二碳六烯酸补充剂与载脂蛋白 E ε4 携带者阿尔茨海默病阶段的关联：综述。
JAMA Neurol. 2017 Mar 1;74(3):339-347. doi: 10.1001/jamaneurol.2016.4899.
3
The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.S-Connect 研究：苏威氨在轻中度阿尔茨海默病中随机对照试验的结果。
Alzheimers Res Ther. 2013 Nov 26;5(6):59. doi: 10.1186/alzrt224. eCollection 2013.
4
Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.苏威澳在轻度阿尔茨海默病中的疗效：一项随机对照试验的结果。
J Alzheimers Dis. 2012;31(1):225-36. doi: 10.3233/JAD-2012-121189.
5
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.医学食品治疗轻度阿尔茨海默病的疗效：一项随机对照试验。
Alzheimers Dement. 2010 Jan;6(1):1-10.e1. doi: 10.1016/j.jalz.2009.10.003.
6
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.阿尔茨海默病诊断的研究标准：修订NINCDS-ADRDA标准
Lancet Neurol. 2007 Aug;6(8):734-46. doi: 10.1016/S1474-4422(07)70178-3.
7
Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally.通过口服尿苷加二十二碳六烯酸，沙土鼠脑中的突触蛋白和磷脂会增加。
Brain Res. 2006 May 9;1088(1):83-92. doi: 10.1016/j.brainres.2006.03.019. Epub 2006 Apr 21.
Zotero 插件